• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 14D9/A filed by Calliditas Therapeutics AB

    9/3/24 4:21:15 PM ET
    $CALT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CALT alert in real time by email
    SC 14D9/A 1 tm2423167d1_sc14d9a.htm SC 14D9/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14D-9

     

    SOLICITATION/RECOMMENDATION STATEMENT

    UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)

     

    Calliditas Therapeutics AB (publ)

    (Name of Subject Company)

     

    Calliditas Therapeutics AB (publ)

    (Name of Person Filing Statement)

     

    American Depositary Shares, each representing two Common Shares,

    quota value SEK 0.04 per share

    Common Shares, quota value SEK 0.04 per share

    (Title of Class of Securities)

     

    13124Q106*

    (CUSIP Number of Class of Securities)

     

    Calliditas Therapeutics AB

    Kungsbron 1, D5

    SE-111 22 Stockholm, Sweden

    Tel: +46 (0) 8 411 3005

    Attn: Renée Aguiar-Lucander, Chief Executive Officer

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications

    on Behalf of the Person Filing Statement)

     

    With copies to:

     

    Joshua A. Kaufman, Esq.

    Sanjay M. Shirodkar, Esq.
    DLA Piper LLP (US)
    1251 Avenue of the Americas
    New York, New York 10020
    (212) 335-4640

     

    Dain Hård Nevonen
    Advokatfirman Vinge KB
    Smålandsgatan 20, Box 1703

    111 87 Stockholm
    +46 (0)10 614 30 96

     

     

    ¨ Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
    * This CUSIP number is assigned to the Subject Company’s American Depositary Shares, each representing two (2) Common Shares.

     

     

     

     

     

     

    This Amendment No. 2 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 filed by Calliditas Therapeutics AB (publ), a public limited liability company organized under the laws of Sweden (“Calliditas” or the “Company”), with the Securities and Exchange Commission (the “SEC”) on July 22, 2024, and amended on August 2, 2024 (as amended or supplemented from time to time, the “Schedule 14D-9”), relating to the tender offer by Asahi Kasei Corporation, a public stock company organized under the laws of Japan (“Asahi Kasei”, or the “Buyer”), to acquire all of the outstanding common shares, quota value SEK 0.04 per share, of Calliditas (each, a “Common Share” and, collectively, the “Common Shares”) held by U.S. persons (the “U.S. Common Shares”) and American Depositary Shares, each representing two Common Shares (each, an “ADS” and, collectively, the “ADSs”) of Calliditas in exchange for SEK 208 per Common Share, representing SEK 416 per ADS, in cash, without interest (such amount per U.S. Common Share and ADS paid pursuant to the U.S. Offer, the “Offer Consideration”) upon the terms and subject to the conditions set forth in the Offer to Purchase, dated July 18, 2024 (together with any amendments or supplements thereto, the “Offer to Purchase”), and in the accompanying Acceptance Form for Shares (together with any amendments or supplements thereto, the “Acceptance Form for Shares” and Letter of Transmittal for ADSs (together with any amendments or supplements thereto, the “ADS Letter of Transmittal” and, together with the Offer to Purchase, the Acceptance Form for Shares and other related materials, as each may be amended or supplemented from time to time, the “U.S. Offer”). The U.S. Offer is being made in conjunction with an offer by the Buyer in Sweden directed to holders of Shares, but not holders of ADSs (the “Swedish Offer,” and together with the U.S. Offer, the “Offers”).

     

    Except to the extent specifically provided in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged. This Amendment is being filed to amend and supplement the Items set forth below.

     

    Item 2. Identity and Background of Filing Person.

     

    Item 2, “Identity and Background of Filing Person—Tender Offer” of the Schedule 14D-9 is hereby amended and supplemented by adding the following language below the last paragraph of such section:

     

    “On September 2, 2024, Buyer announced that the Offers and withdrawal rights expired as scheduled at the Initial Expiration Time (6:00 p.m., Eastern time, on August 30, 2024). Skandinaviska Enskilda Banken, the tender agent for the Shares, has advised Buyer that, as of 6:00 p.m., Eastern time, on August 30, 2024, approximately 42,988,491 Shares have been validly tendered and not properly withdrawn pursuant to the Offers. Computershare Trust Company, N.A., the tender agent for the ADSs, has advised Buyer that, as of 6:00 p.m., Eastern time, on August 30, 2024, approximately 1,028,600 ADSs have been validly tendered and not properly withdrawn pursuant to the Offers. These Shares and ADSs collectively represent approximately 83.37% of the outstanding Shares as of such time. This means that Asahi Kasei, together with shares acquired by Asahi Kasei outside the Offers in accordance with applicable law, will own shares and ADSs corresponding to a total of 93.30% of all shares of Calliditas upon settlement of the Offers. As a result, the Minimum Tender Condition was satisfied as of the Initial Expiration Time. As the Minimum Tender Condition and each of the other conditions to the Offers have been satisfied, on September 2, 2024, Buyer accepted for payment all Offer Securities that were validly tendered and not properly withdrawn pursuant to the Offers.

     

    Also on September 2, 2024, Buyer announced its intention to initiate compulsory redemption proceedings and to commence a subsequent offering period of the U.S. Offer (the “Subsequent U.S. Offering Period”) in accordance with Rule 14d-11 promulgated under the Exchange Act. The Subsequent U.S. Offering Period will expire at 6:00 p.m., Eastern time, on September 13, 2024, unless otherwise extended. All Offer Securities validly tendered during the Subsequent U.S. Offering Period will be immediately accepted for payment, and tendering holders will thereafter promptly be paid the same Offer Consideration of SEK 416 per ADS, upon the terms and subject to the conditions set forth in the Offer to Purchase. The procedures for accepting the U.S. Offer and tendering Offer Securities during the Subsequent Offering Period are the same as those applicable to the U.S. Offer as described in the Offer to Purchase, except that Shares and ADSs validly tendered during the Subsequent U.S. Offering Period may not be withdrawn pursuant to Rule 14d-7(a)(2) promulgated under the Securities Exchange Act of 1934, as amended. The Subsequent U.S. Offering Period is being made in conjunction with a subsequent offering period by Buyer in Sweden of the Swedish Offer, which is directed to holders of Shares, but not holders of ADSs.

     

     

     

     

    Pursuant to a request from the Buyer, the Company has submitted a notice of termination to the ADS depositary, notified Nasdaq of its intention to voluntarily delist the ADSs from Nasdaq and filed a Form 25, Notification of Removal from Listing and/or Registration with the SEC, thereby commencing the process of delisting the ADSs and terminating the ADS program. Provided that the criteria for deregistration are met, the Company also intends to terminate its reporting obligations under the Exchange Act by filing the requisite documents with the SEC. Following delisting from Nasdaq, the ADSs will not be listed or registered on another national securities exchange. Delisting is likely to reduce significantly the liquidity and marketability of any ADSs that have not been tendered pursuant to the U.S. Offer or the Subsequent U.S. Offering Period.

     

    In order to facilitate the completion of the Offers, the Company has entered into an amendment to its credit agreement with Athyrium Capital Management, LP (“Athyrium”) to provide for an extension of the date by which the credit facility is required to be repaid, in exchange for certain payments based on the date of repayment. In connection with this amendment, the Company also entered into a loan agreement with Asahi Kasei (the “Asahi Kasei Loan Agreement”) to fund the repayment to Athyrium. Pursuant to the Asahi Kasei Loan Agreement, the Buyer has agreed to lend to the Company the sum of $133 million, in accordance with the terms and conditions set forth therein for the purposes of long term funding and financing certain change of control obligations due by the Company pursuant to its credit agreement with Athyrium. The rate of interest of the Asahi Kasei Loan Agreement is 4.69% per annum. The Interest Payment Date will be March 20 and September 20 in each year and on the Maturity Date, with each Interest Period being the period commencing on each Interest Payment Date and ending on each Subsequent Interest Payment Date, provided that the 1st Interest Period commences on the Disbursement Date and ends on March 20, 2025 (in each case, as defined therein). The Company may prepay the principal of the loan in whole or in part before September 20, 2028, subject to certain conditions as described therein, and Buyer may, upon written notice to the Company, declare the payment of the principal of and any accrued interest in respect of the loan to be due upon the occurrence of certain events as further described therein.”

     

    Item 9. Exhibits.

     

    Item 9 of the Schedule 14D-9 is hereby amended and supplemented by adding the following exhibit:

     

    Exhibit No.   Description
    (a)(5)(H)   Press release issued by the Company (incorporated by reference to Exhibit 99.1 of the Form 6-K filed by the Company with the SEC on September 3, 2024).
    (a)(5)(I)   Press release issued by Asahi Kasei (incorporated by reference to Exhibit (a)(5)(R) of the Schedule TO/A filed by Asahi Kasei with the SEC on September 3, 2024).
    (a)(5)(J)   English version of press release issued by Asahi Kasei (incorporated by reference to Exhibit (a)(5)(S) of the Schedule TO/A filed by Asahi Kasei with the SEC on September 3, 2024).

     

     

     

     

    SIGNATURE

     

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 14D-9 is true, complete and correct.

     

      CALLIDITAS THERAPEUTICS AB (PUBL)
       
    Date: September 3, 2024 By: /s/ Renée Aguiar-Lucander
      Name:   Renée Aguiar-Lucander
      Title:  Chief Executive Officer

     

     

    Get the next $CALT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CALT

    DatePrice TargetRatingAnalyst
    6/20/2023$60.00Buy
    H.C. Wainwright
    3/1/2023$18.00Neutral
    Guggenheim
    12/20/2021$52.00 → $62.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CALT
    SEC Filings

    See more
    • SEC Form 15F-12B filed by Calliditas Therapeutics AB

      15F-12B - Calliditas Therapeutics AB (0001795579) (Filer)

      9/23/24 4:44:35 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Calliditas Therapeutics AB

      25-NSE - Calliditas Therapeutics AB (0001795579) (Subject)

      9/20/24 4:45:11 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC TO-T/A filed by Calliditas Therapeutics AB

      SC TO-T/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/18/24 9:02:28 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Calliditas Therapeutics AB with a new price target

      H.C. Wainwright initiated coverage of Calliditas Therapeutics AB with a rating of Buy and set a new price target of $60.00

      6/20/23 7:20:21 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Calliditas Therapeutics AB with a new price target

      Guggenheim initiated coverage of Calliditas Therapeutics AB with a rating of Neutral and set a new price target of $18.00

      3/1/23 6:14:34 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Calliditas Therapeutics with a new price target

      HC Wainwright & Co. reiterated coverage of Calliditas Therapeutics with a rating of Buy and set a new price target of $62.00 from $52.00 previously

      12/20/21 6:22:01 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TARPEYO issued to CALLIDITAS THERAPEUTICS AB

      Submission status for CALLIDITAS THERAPEUTICS AB's drug TARPEYO (ORIG-1) with active ingredient BUDESONIDE has changed to 'Approval' on 12/15/2021. Application Category: NDA, Application Number: 215935, Application Classification: Type 5 - New Formulation or New Manufacturer

      12/20/21 3:40:41 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm

      STOCKHOLM, Sept. 16, 2024 /PRNewswire/ -- Nasdaq Stockholm has decided that Calliditas Therapeutics AB (publ) will be delisted from Nasdaq Stockholm. The last day of trading in the share will be on Thursday, October 10, 2024. For further information, please contact: Åsa Hillsten, Head of IR & Sustainability, Calliditas Tel.: +46 76 403 35 43, Email: [email protected] The information was sent for publication, through the agency of the contact person set out above, on September 16, 2024 at 15:30 CET. About Calliditas Calliditas Therapeutics is a biopharma company headquartered in Stockholm, Sweden, focused on identifying, developing, and commercializing novel treatments in orphan in

      9/16/24 9:46:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- The shareholders of Calliditas Therapeutics AB (publ) ("Calliditas Therapeutics"), Reg. No. 556659-9766, with registered office in Stockholm, are summoned to the extraordinary general meeting on Monday 30 September 2024 at 12:00 p.m. CEST at Advokatfirman Vinge's premises on Smålandsgatan 20, SE-111 46, Stockholm, Sweden. Registration starts at 11:30 a.m. CEST. Background Asahi Kasei Corporation ("Asahi Kasei"), which has announced that the public offer made regarding the company's shares has been accepted to such extent that Asahi Kasei becomes the owner of more than 90 per cent of the shares and votes in the company, has requested the board of dire

      9/3/24 7:13:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

      STOCKHOLM, Sept. 3, 2024 /PRNewswire/ -- Following the announcement by Asahi Kasei Corporation ("Asahi Kasei") on September 2, 2024 that it controls more than 90 percent of the outstanding shares of Calliditas Therapeutics AB (NASDAQ:CALT) ("Calliditas" or the "Company"), and declared its offers to purchase all of the outstanding Common Shares and ADSs of Calliditas unconditional and intends to initiate compulsory redemption of the remaining shares of the Company, the Board of Directors of Calliditas has resolved, in accordance with a request from Asahi Kasei, to take certain corporate actions. Delisting of Common Shares and Delisting, Deregistration, and Termination of ADS Program In light

      9/3/24 6:31:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/23/24 7:32:15 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Calliditas Therapeutics AB

      SC 13D/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/17/24 7:55:03 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Calliditas Therapeutics AB

      SC 13G/A - Calliditas Therapeutics AB (0001795579) (Subject)

      9/11/24 7:42:16 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Financials

    Live finance-specific insights

    See more
    • Calliditas Interim Report January to June 2024

      STOCKHOLM, Aug. 13, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (STO: CALTX) : April to June 2024 (compared to April to June 2023) Net sales amounted to SEK 559.8 million, of which TARPEYO® net sales amounted to SEK 493.4 million, for the three months ended June 30, 2024. For the three months ended June 30, 2023, net sales amounted to SEK 269.4 million, of which TARPEYO net sales amounted to SEK 259.2 million.Operating loss amounted to SEK 31.5 million and SEK 75.2 million for the three months ended June 30, 2024, and 2023, respectively. However, expenses related to the Asahi Kasei offer and expenses related to provisions for social security contribution for incentive prog

      8/13/24 1:22:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Invitation to the presentation of Calliditas's interim report January - June 2024

      STOCKHOLM, Aug. 5, 2024 /PRNewswire/ -- Calliditas's interim report for the second quarter, April - June 2024 will be published in Swedish and English on Tuesday 13 August 2024 at 07.00 a.m. CET. A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén. The presentation will be given in English. Link to the webcast:  https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024 To participate via conference call please register via this link: https://conference.financialhearings.com/tel

      8/5/24 1:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

      STOCKHOLM, June 17, 2024 /PRNewswire/ -- The following resolutions were passed at Calliditas Therapeutics AB (publ) ("Calliditas") annual general meeting held today, on 17 June 2024, in Stockholm. Adoption of income statement and balance sheet for the financial year 2023 and discharge from liability The annual general meeting resolved to adopt the income statement and the consolidated income statement for the financial year 2023 as well as the balance sheet and consolidated balance sheet as of 31 December 2023. The members of the Board of Directors and the CEO were discharged from liability for the financial year 2023. Allocation of profit or loss                                            

      6/17/24 12:01:00 PM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CALT
    Leadership Updates

    Live Leadership Updates

    See more
    • Calliditas Therapeutics appoints Maria Törnsén as President North America

      STOCKHOLM, Jan. 7, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ:CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), a commercial biopharma company focused on rare diseases today announced that Maria Törnsén has been appointed to the position of President North America. Ms Törnsén will be responsible for all US based operations and will report to the CEO. Maria Törnsén has broad commercial leadership experience having spent more than 20 years in the biopharma industry in senior commercial roles. Most recently Ms Törnsén held the position of Chief Commercial Officer at Passage Bio, prior to which she was SVP General Manager US at Sarepta Therapeutics. Prior to joining Sarepta she serv

      1/7/24 11:19:00 AM ET
      $CALT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

      FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson to the position of Chief Financial and Business Officer. Ms. Henderson will join the Company effective April 5, 2022.       Ms. Henderson most recently served as Chief Financial Officer of UroGen Pharma (NASDAQ:URGN), a commercial-stage biopharmaceutical company focused on building novel treatments for specialty cancers and urologic disease. She brings over two decades of global finance expertise and has

      3/22/22 8:02:00 AM ET
      $CALT
      $PHAT
      $URGN
      Biotechnology: Pharmaceutical Preparations
      Health Care